Evidence map›Paper›PMID 32943538›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.

Jan C Holter, Soeren E Pischke, Eline de Boer, Andreas Lind, Synne Jenum, Aleksander R Holten, Kristian Tonby, Andreas Barratt-Due, Marina Sokolova, Camilla Schjalm and 22 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 249 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
249citing papers in PubMed, 2 pooled it
25.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

249 citing papers in PubMed, 2 syntheses or guidelines pooled it, 411 citations in OpenAlex.

  1. Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025
    Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

189 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 3 institutions in 1 country.

Jan C HolterDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0003-1618-5022
Soeren E PischkeInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway; s.e.pischke@medisin.uio.no.ORCID 0000-0003-2543-3251
Eline de BoerInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Andreas LindDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0002-8289-8410
Synne JenumDepartment of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0001-8187-775X
Aleksander R HoltenInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0001-7916-0717
Kristian TonbyInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Andreas Barratt-DueInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0001-5408-7162
Marina SokolovaInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0002-0062-3369
Camilla SchjalmInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Viktoriia ChabanInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Anette KolderupInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Trung TranDepartment of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
Torleif Tollefsrud GjølbergInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Linda G SkeieDepartment of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.
Liv HesstvedtDepartment of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0003-1582-171X
Vidar OrmåsenInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0002-7766-3027
Børre FevangResearch Institute of Internal Medicine, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0001-6828-0609
Cathrine AustadDepartment of Internal Medicine, Vestre Viken Hospital Trust, 3004 Drammen, Norway.
Karl Erik MüllerDepartment of Internal Medicine, Vestre Viken Hospital Trust, 3004 Drammen, Norway.ORCID 0000-0003-4020-9733
Cathrine FladebyDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
Mona Holberg-PetersenDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
Bente HalvorsenInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Fredrik MüllerDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0001-8934-2784
Pål AukrustInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0002-6509-6221
Susanne DudmanDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0001-5047-4982
Thor UelandInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Jan Terje AndersenInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Fridtjof Lund-JohansenDepartment of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
Lars HeggelundDepartment of Internal Medicine, Vestre Viken Hospital Trust, 3004 Drammen, Norway.ORCID 0000-0002-1669-1032
Anne M Dyrhol-RiiseInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Tom E MollnesInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0002-5785-802X
Oslo University Hospital · NOVestre Viken Hospital Trust · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory failure in the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is hypothesized to be driven by an overreacting innate immune response, where the complement system is a key player. In this prospective cohort study of 39 hospitalized coronavirus disease COVID-19 patients, we describe systemic complement activation and its association with development of respiratory failure. Clinical data and biological samples were obtained at admission, days 3 to 5, and days 7 to 10. Respiratory failure was defined as PO

Indexed as

Complement ActivationAgedBetacoronavirusBiomarkersCase-Control StudiesCoronavirus InfectionsCOVID-19FemaleHost-Pathogen InteractionsHumansMaleMannose-Binding LectinMiddle AgedPandemicsPneumonia, ViralRespiratory InsufficiencyBiomarkersMannose-Binding Lectincomplement systemCOVID-19respiratory failureSARS-CoV-2sC5b-9

Identifiers

PMID32943538
PMCPMC7547220
OpenAlexW3085326737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.